ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Biologics"

  • Abstract Number: 874 • 2013 ACR/ARHP Annual Meeting

    Sustained and Consistent Clinical Benefit With Intravenous Golimumab Therapy In Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy:  Results Through 1-Year Of a Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial

    Clifton O. Bingham III1, Rene Westhovens2, Alan M. Mendelsohn3, Lilianne Kim4, Kim Hung Lo4 and Michael E. Weinblatt5, 1Rheumatology, Johns Hopkins University, Baltimore, MD, 2Rheumatology, University Hospital KU Leuven, Leuven, Belgium, 3Immunology, Janssen Research & Development, LLC., Spring House, PA, 4Janssen Research & Development, LLC., Spring House, PA, 5Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA

      Background/Purpose: To report on sustainability and consistency of ACR component scores with intravenous (IV) golimumab (GLM) 2mg/kg+methotrexate (MTX) through wk52 in pts with active rheumatoid…
  • Abstract Number: 323 • 2013 ACR/ARHP Annual Meeting

    Safety Of Ustekinumab From The Placebo-Controlled Periods Of Psoriatic Arthritis and Psoriasis Clinical Developmental Programs

    Iain B. McInnes1, Kim Papp2, Lluis Puig3, Kristian Reich4, Christopher T. Ritchlin5, Bruce Strober6, Proton Rahman7, Arthur Kavanaugh8, Alan M. Mendelsohn9, Michael Song10, Daphne Chan10, Yaung-Kaung Shen10, Shu Li10 and Alice B. Gottlieb11, 1Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, 2Probity Research, Waterloo, ON, Canada, 3Universitat Autònoma de Barcelona, Barcelona, Spain, 4SCIderm Research Institute and Dermatologikum Hamburg, Hamburg, Germany, 5Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, 6University of Connecticut, Farmington, CT, 7Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, 8University of California, San Diego, La Jolla, CA, 9Immunology, Janssen Research & Development, LLC., Spring House, PA, 10Janssen Research & Development, LLC., Spring House, PA, 11Tufts Medical Center, Boston, MA

    Background/Purpose:   To describe the short-term safety experience of UST during the double-blind, PBO-controlled portion of the PsA & PsO clinical developmental programs. Methods: Safety…
  • Abstract Number: L11 • 2012 ACR/ARHP Annual Meeting

    First in Patient Study of Anti-GM-CSF Monoclonal Antibody (MOR103) in Active Rheumatoid Arthritis: Results of a Phase 1b/2a Randomized, Double-Blind, Placebo-Controlled Trial

    Frank Behrens1, Mikkel Ostergaard2, Rumen Stoilov3, Piotr Wiland4, Thomas W. Huizinga5, Vadym Y. Berenfus6, Paul-Peter Tak7, Stoyanka Vladeva8, Juergen Rech9, Andrea Rubbert-Roth10, Mariusz Korkosz11, Dmitriy Rekalov12, Igor A. Zupanets13, Bo J. Ejbjerg14, Jens Geiseler15, Julia Fresenius15, Roman P. Korolkiewicz16, Arndt J. Schottelius16 and Harald Burkhardt1, 1CIRI /Div. of Rheumatology, Goethe-University, Frankfurt/Main, Germany, 2Copenhagen Center for Arthritis Research, Copenhagen University Hospital at Glostrup, Glostrup, Denmark, 3Clinic of rheumatology, University Hospital (MHAT) St. Ivan Rilski, Sofia, Bulgaria, 4Department of Rheumatology, Medical University of Wroclaw, Wroclaw, Poland, 5Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 6Occupational Diseases, Regional Clinical Hospital, Donetsk, Ukraine, 7Academic Medical Center / currently also GlaxoSmithKline, Amsterdam, Netherlands, 8Second Internal Clinic UMHAT Stara Zagora, Stara Zagora, Bulgaria, 9Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, 10Internal Medicine I, University of Cologne, Cologne, Germany, 11Malopolskie Centrum Medyczne, Krakow, Poland, 12Department of Internal Diseases, Zaporizhzhia Regional Hospital, Zaporozhe, Ukraine, 13Clinical and Diagnostics Centre of National Pharmaceutical University MOH of Ukraine, Kharkiv, Ukraine, 14Slagelse Sygehus, Slagelse, Denmark, 15Asklepios Clinic Munich-Gauting, Gauting, Germany, 16Development, MorphoSys AG, Martinsried/Planegg, Germany

    Background/Purpose: MOR103, a human mAb targeting GM-CSF, is being evaluated for treatment of rheumatoid arthritis (RA). Pre-clinical studies on cytokine function and investigations in experimental…
  • « Previous Page
  • 1
  • …
  • 27
  • 28
  • 29
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology